SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

ConditionsLaryngeal Cancer Hypopharynx Cancer

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-70

SponsorSun Yat-sen University

About this trial

This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Eligibility criteria

Qualifiers

Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th

age 18-70

PS score 0-1

normal functions to tolerate chemotherapy, immunotherapy and radiotherapy

Disqualifiers

Patients with a combination of other malignant tumours

Individuals with contraindications to immunotherapy

Trial design

Treatments tested in this trial

SBRT+Toripalimab Plus Docetaxel and Cisplatin

Treatment groups

35 Participants

are divided into 1 treatment group

Sponsors and collaborators

Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov